Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26

Goldman Sachs analyst Salveen Richter has initiated coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating. The firm has set a price target of $26 for the stock.